Similar articles for PMID: 15564551

Year	Number of Results
1999	2
2000	3
2001	7
2002	3
2003	4
2004	9
2005	10
2006	4
2007	13
2008	5
2009	17
2010	6
2011	7
2012	3
2013	4
2014	3
2016	1
2024	0

1

Breast cancer--loss of PTEN predicts resistance to treatment.

Pandolfi PP. Pandolfi PP. N Engl J Med. 2004 Nov 25;351(22):2337-8. doi: 10.1056/NEJMcibr043143. N Engl J Med. 2004. PMID: 15564551 No abstract available.

2

Successful targeting of ErbB2 receptors-is PTEN the key?

Crowder RJ, Lombardi DP, Ellis MJ. Crowder RJ, et al. Cancer Cell. 2004 Aug;6(2):103-4. doi: 10.1016/j.ccr.2004.08.001. Cancer Cell. 2004. PMID: 15324690 Free article.

3

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. Nagata Y, et al. Cancer Cell. 2004 Aug;6(2):117-27. doi: 10.1016/j.ccr.2004.06.022. Cancer Cell. 2004. PMID: 15324695 Free article.

4

PTEN activation may contribute to exquisite antitumor response to trastuzumab.

Altundag K, Altundag O, Morandi P, Gunduz M. Altundag K, et al. Breast. 2005 Apr;14(2):175; author reply 176. doi: 10.1016/j.breast.2004.09.009. Breast. 2005. PMID: 15767191 No abstract available.

5

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, van de Vijver MJ, Bernards R. Berns K, et al. Cancer Cell. 2007 Oct;12(4):395-402. doi: 10.1016/j.ccr.2007.08.030. Cancer Cell. 2007. PMID: 17936563 Free article. Clinical Trial.

6

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer.

Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ. Nahta R, et al. Nat Clin Pract Oncol. 2006 May;3(5):269-80. doi: 10.1038/ncponc0509. Nat Clin Pract Oncol. 2006. PMID: 16683005 Review.

7

PI3 kinase activation and response to Trastuzumab Therapy: what's neu with herceptin resistance?

Park BH, Davidson NE. Park BH, et al. Cancer Cell. 2007 Oct;12(4):297-9. doi: 10.1016/j.ccr.2007.10.004. Cancer Cell. 2007. PMID: 17936554 Free article.

8

Trastuzumab: mechanisms of resistance and therapeutic opportunities.

Calabrich A, Fernandes Gdos S, Katz A. Calabrich A, et al. Oncology (Williston Park). 2008 Oct;22(11):1250-8; discussion 1259, 1263. Oncology (Williston Park). 2008. PMID: 18980023 Free article. Review.

9

[Trastuzumab (Herceptin) and breast cancer: mechanisms of resistance].

Dieras V, Vincent-Salomon A, Degeorges A, Beuzeboc P, Mignot L, de Cremoux P. Dieras V, et al. Bull Cancer. 2007 Mar;94(3):259-66. Bull Cancer. 2007. PMID: 17371768 Free article. Review. French.

10

Mechanisms of trastuzumab resistance and their clinical implications.

Lan KH, Lu CH, Yu D. Lan KH, et al. Ann N Y Acad Sci. 2005 Nov;1059:70-5. doi: 10.1196/annals.1339.026. Ann N Y Acad Sci. 2005. PMID: 16382045 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

95 results

Results by year